ReviewCureus2026
Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine represents a widespread neurological disorder that causes substantial disability and impacts on quality of life and functioning. An oral calcitonin gene-related peptide (CGRP) receptor antagonist, atogepant, is a new targeted preventive treatment for migraine. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety profile of atogepant in migraine prevention. According to the PRISMA guidelines, relevant studies were identified through a thorough database search in the PubMed, Cochrane, and ScienceDirect databases to identify all randomized controlled trials (RCTs) evaluating atogepant in adults with episodic or chronic migraine. A total of six high-quality RCTs and 3,453 patients were included. The outcomes evaluated were monthly migraine days (MMDs), monthly headache days (MHDs), acute migraine medication use, and adverse events. Pooled analysis demonstrated that atogepant significantly reduced MMDs (mean difference (MD) = -1.47; 95% CI -1.73 to -1.21), MHDs (MD = -1.71; 95% CI -1.95 to -1.48), and acute migraine medication use (MD = -1.69; 95% CI -1.94 to -1.44) compared with placebo across dose levels. Higher doses with reductions were observed, particularly with the 60 mg once-daily and 30 mg twice-daily doses. Atogepant was effective in hard-to-treat populations such as those with chronic migraine and headaches related to medication overuse. The overall risk of adverse events was slightly higher with atogepant than with placebo (RR = 1.13; 95% CI 1.01 to 1.25), although most events were mild to moderate, including nausea, constipation, fatigue, and decreased appetite. Findings from the subgroup analyses indicated that the 30 mg twice-daily regimen may be linked to an increased risk of adverse events, suggesting differences in tolerability between doses. In general, atogepant was well tolerated and safe, demonstrating good safety and tolerability relative to other traditional preventive migraine medications. This study provides evidence supporting the effectiveness and tolerability of atogepant as an oral preventive treatment for episodic and chronic migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.